StreetInsider.com News Articles

William Blair Resumes uniQure BV (QURE) at Outperform

Wed, 02 Sep 2026 06:42:25 -0400

William Blair analyst Sami Corwin resumes coverage on uniQure BV (NASDAQ: QURE) with a Outperform rating.

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $47.86 yesterday.

Form SCHEDULE 13G/A uniQure N.V. Filed by: SUSQUEHANNA SECURITIES, LLC

Fri, 14 Aug 2026 14:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26928724.html

Form SCHEDULE 13G/A uniQure N.V. Filed by: SUSQUEHANNA SECURITIES, LLC

Fri, 14 Aug 2026 14:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26928724.html

Form SCHEDULE 13G uniQure N.V. Filed by: RTW INVESTMENTS, LP

Fri, 14 Aug 2026 08:18:00 -0400

si-local-file:///var/storage/secattach/20260814/26925005.html

Form SCHEDULE 13G uniQure N.V. Filed by: RTW INVESTMENTS, LP

Fri, 14 Aug 2026 08:18:00 -0400

si-local-file:///var/storage/secattach/20260814/26925005.html

uniQure BV (QURE) PT Raised to $75 at Wells Fargo

Thu, 30 Jul 2026 08:35:40 -0400

Wells Fargo analyst Yanan Zhu raised the price target on uniQure BV (NASDAQ: QURE) to $75.00 (from $60.00) while maintaining a Overweight rating.

uniQure BV (QURE) PT Lowered to $60 at Barclays

Thu, 30 Jul 2026 04:59:01 -0400

Barclays analyst Eliana Merle lowered the price target on uniQure BV (NASDAQ: QURE) to $60.00 (from $65.00) while maintaining a Overweight rating.

Wolfe Research Upgrades uniQure BV (QURE) to Outperform

Wed, 29 Jul 2026 16:19:39 -0400

Wolfe Research analyst Rudy Li upgraded uniQure BV (NASDAQ: QURE) from Peerperform to Outperform with a price target of $65.00.

The analyst comments "The stock has priced in <50% POS for approval amid concerns stemming from the recent AdComs, but in our view, QURE has a stronger case than the market appreciates. We model 70% POS and $2B US peak sales for AMT-130, upgrading to OP with $65 PT."

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $36.66 yesterday.

Wolfe Research Upgrades uniQure BV (QURE) to Outperform

Wed, 29 Jul 2026 16:19:39 -0400

Wolfe Research analyst Rudy Li upgraded uniQure BV (NASDAQ: QURE) from Peerperform to Outperform with a price target of $65.00.

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $36.66 yesterday.

uniQure (QURE) Misses Q2 EPS by 38c

Wed, 29 Jul 2026 07:30:37 -0400

uniQure (NASDAQ: QURE) reported Q2 EPS of ($1.22), $0.38 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $5.84 million versus the consensus estimate of $5.49 million.

For earnings history and earnings-related data on uniQure (QURE) click here.

Form S-8 uniQure N.V.

Wed, 29 Jul 2026 07:29:00 -0400

si-local-file:///var/storage/secattach/20260729/26830596.html

Form S-8 uniQure N.V.

Wed, 29 Jul 2026 07:29:00 -0400

si-local-file:///var/storage/secattach/20260729/26830596.html

Form 10-Q uniQure N.V. For: Jun 30

Wed, 29 Jul 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260729/26830548.html

Form 10-Q uniQure N.V. For: Jun 30

Wed, 29 Jul 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260729/26830548.html

Form 8-K uniQure N.V. For: Jul 29

Wed, 29 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260729/26830463.html

Form 8-K uniQure N.V. For: Jul 29

Wed, 29 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260729/26830463.html

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130